Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Brainsway (BWAY) Stock Price & Analysis

2 Followers

BWAY Stock Chart & Stats

ILA 3,653.00ILA 164.00(4.70%)
At close:
ILA 3.5KILA 4KILA 4.5KILA 5KAug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
ILA 3,489.00 - ILA 3,699.00
52-Week Range
ILA 2,391.00 - ILA 5,165.00
Previous Close
ILA 3,489.00
Volume
N/A
Average Volume (3M)
77.96K
Market Cap
ILS 1.40B
Enterprise Value
ILS 1.68B
Total Cash (Recent Filing)
ILS 61.94M
Total Debt (Recent Filing)
ILS 7.13M
Price to Earnings (P/E)
45.4
Beta
0.64
Next Earnings
Nov 10, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Installed-Base Growth

Strong revenue growth alongside a larger installed base supports durable expansion of the company’s provider footprint. Remaining performance obligations and multiyear agreements improve forward revenue visibility, while broader deployment can increase recurring service and utilization-linked revenue over time.

Margin And Profitability Expansion

Improving gross and operating margins indicate that revenue growth is translating into stronger operating leverage rather than merely higher volume. Management also expects gross-margin benefits to remain sustainable into 2027, supporting the potential for earnings growth as the business scales.

Conservative Balance Sheet

Low leverage gives BrainsWay financial flexibility to invest in clinical development, international expansion and commercial initiatives without substantial refinancing pressure. The combination of expanding equity and improved returns also strengthens resilience as the company funds its next phase of growth.

Bears Say

Free-Cash-Flow Volatility

Profitability has improved, but weaker 2026 TTM cash conversion shows that earnings are not consistently translating into available cash. Persistent working-capital swings or higher cash costs could constrain internally funded expansion and make financial performance less predictable over the next several quarters.

Rising Operating Expenses

Higher commercial, research and administrative spending can support expansion, but it also raises the execution burden required to preserve operating leverage. If expense growth continues faster than revenue or margin gains, it could limit the durability of recent profitability improvements.

Unproven Clinical Expansion Opportunities

Potential expansion into Alzheimer's disease and suicidal-ideation treatment remains dependent on additional evidence and regulatory progress. Small preliminary findings may not translate into approval or adoption, creating uncertainty around how much these indications can contribute to the durable growth profile.

Brainsway News

BWAY FAQ

What was Brainsway’s price range in the past 12 months?
Brainsway lowest stock price was ILA 2391.00 and its highest was ILA 5165.00 in the past 12 months.
What is Brainsway’s market cap?
Brainsway’s market cap is ₪1.40B.
When is Brainsway’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Brainsway’s earnings last quarter?
Brainsway released its earnings results on Aug 12, 2026. The company reported ILA 20 earnings per share for the quarter.
Is Brainsway overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Brainsway pay dividends?
Brainsway does not currently pay dividends.
What is Brainsway’s EPS estimate?
Brainsway’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainsway have?
Brainsway has 40,252,990 shares outstanding.
What happened to Brainsway’s price movement after its last earnings report?
Brainsway reported an EPS of ILA 20 in its last earnings report. Following the earnings report the stock price went up 3.753%.
Which hedge fund is a major shareholder of Brainsway?
Currently, no hedge funds are holding shares in IL:BWAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology